Pfiz­er launch­es re­bate pro­gram for rare dis­ease pa­tients who have to stop tak­ing Panzy­ga

Pfiz­er is launch­ing its sec­ond-ever re­bate pro­gram, this time for Panzy­ga, its treat­ment for a rare neu­ro­log­i­cal dis­ease of the pe­riph­er­al nerves.

The pro­gram be­gan last month, ac­cord­ing to STAT which first re­port­ed the news, and of­fers a re­fund of out-of-pock­et costs for pa­tients who must dis­con­tin­ue their course be­fore the fifth treat­ment for “clin­i­cal rea­sons.”

Panzy­ga was ap­proved back in 2018 to treat pri­ma­ry im­mun­od­e­fi­cien­cy (PI) in pa­tients two years and old­er and chron­ic im­mune throm­bo­cy­tope­nia (cITP) in adults. It has since picked up an in­di­ca­tion in chron­ic in­flam­ma­to­ry de­myeli­nat­ing polyneu­ropa­thy (CIDP), a con­di­tion that’s char­ac­ter­ized by weak­ness of the arms or legs, tin­gling or numb­ness, and a loss of deep ten­don re­flex­es, ac­cord­ing to the NIH.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER